Skip to main content
Erschienen in: Supportive Care in Cancer 7/2014

01.07.2014 | Original Article

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice

verfasst von: Mary Lou Affronti, Susan M. Schneider, James E. Herndon II, Susan Schlundt, Henry S. Friedman

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant glioma patients treated with moderately emetic chemotherapy (MEC). Poorly controlled chemotherapy-induced nausea and vomiting (CINV) reduce cancer treatment efficacy and significantly impair cancer patients’ quality of life (QOL). A review of Duke University Preston Robert Tisch Brain Tumor Center (PRTBTC)’s usual practice demonstrates a high incidence (45 %) of CINV, despite premedication with short-acting 5-HT3-serotonin-receptor antagonists (5-HT3-RAs). National Comprehensive Cancer Network (NCCN)’s evidence-based guidelines recommend the combination of the long-acting 5-HT3-RA palonosetron (PAL) and dexamethasone (DEX) for the prevention of acute and delayed CINV with MEC. Low adherence (58 %) to antiemetic guidelines may have explained our high CINV incidence.

Methods

One-sample binomial test, quasi-experimental design, evaluated a combination intervention that included a provider education session; implementation of risk-assessment tool with computerized, standardized antiemetic guideline order sets; and a monthly audit-feedback strategy. Post-implementation adherence to evidence-based antiemetic order sets and patient outcomes were measured and compared to baseline and historical data. Primary outcome was the guideline order set adherence rate. Secondary outcomes included nausea/vomiting rates and QOL.

Results

Adherence to ordering MEC guideline antiemetics increased significantly, from 58 % to a sustained 90 %, with associated improvement in nausea/vomiting. In acute and delayed phases, 75 and 84 % of patients, respectively, did not experience CINV. There was no significant change in QOL.

Conclusion

Combination intervention and audit-feedback strategy to translate evidence into oncology practice improved and sustained adherence to antiemetic guidelines. Adherence corresponded with effective nausea/vomiting control and preserved QOL in patients with malignant gliomas.
Literatur
1.
Zurück zum Zitat Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16):2563–2569. doi:10.1200/JCO.2005.04.5963 PubMedCrossRef Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16):2563–2569. doi:10.​1200/​JCO.​2005.​04.​5963 PubMedCrossRef
2.
Zurück zum Zitat Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219–227. doi:10.1007/s00520-004-0710-6 PubMedCrossRef Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219–227. doi:10.​1007/​s00520-004-0710-6 PubMedCrossRef
5.
Zurück zum Zitat Wickham R (2010) Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol 8(2 Suppl 1):10–15PubMed Wickham R (2010) Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol 8(2 Suppl 1):10–15PubMed
6.
Zurück zum Zitat Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259. doi:10.1158/1078-0432.CCR-06-2309 PubMedCrossRef Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259. doi:10.​1158/​1078-0432.​CCR-06-2309 PubMedCrossRef
7.
Zurück zum Zitat Affronti ML, Brickhouse A, Marcello J, Herndon J, Reardon DA, Desjardins A, Vredenburgh J (2009) Phase II single arm trial of palonosetron (PALO) for the prevention of acute and delayed chemotherapy induced nausea and vomiting (CINV) in malignant glioma (MG) patients receiving irinotecan in combination with bevacizumab. In: Society of Neuro-Oncology Annual Meeting. J Neuro-Oncol 5:656. doi:10.1215/15228517-2009- 034272.pub2 Affronti ML, Brickhouse A, Marcello J, Herndon J, Reardon DA, Desjardins A, Vredenburgh J (2009) Phase II single arm trial of palonosetron (PALO) for the prevention of acute and delayed chemotherapy induced nausea and vomiting (CINV) in malignant glioma (MG) patients receiving irinotecan in combination with bevacizumab. In: Society of Neuro-Oncology Annual Meeting. J Neuro-Oncol 5:656. doi:10.​1215/​15228517-2009- 034272.​pub2
8.
Zurück zum Zitat Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098. doi:10.1002/cncr.11433 PubMedCrossRef Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098. doi:10.​1002/​cncr.​11433 PubMedCrossRef
10.
Zurück zum Zitat Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261–2268. doi:10.1002/cncr.20230 PubMedCrossRef Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261–2268. doi:10.​1002/​cncr.​20230 PubMedCrossRef
11.
Zurück zum Zitat Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971–2994PubMed Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971–2994PubMed
12.
Zurück zum Zitat Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85–96. doi:10.1007/s00520-004-0699-x PubMedCrossRef Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85–96. doi:10.​1007/​s00520-004-0699-x PubMedCrossRef
15.
Zurück zum Zitat Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19(6):823–832. doi:10.1007/s00520-010-0908-8 PubMedCrossRef Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19(6):823–832. doi:10.​1007/​s00520-010-0908-8 PubMedCrossRef
16.
Zurück zum Zitat Barbour SY, Morrow GR, Ahmed G, Ballinari MD, Cox TD, Schwartzberg LS (2011) Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). In: American Society of Clinical Oncology. Journal of Clinical Oncology 15: p 572 Barbour SY, Morrow GR, Ahmed G, Ballinari MD, Cox TD, Schwartzberg LS (2011) Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). In: American Society of Clinical Oncology. Journal of Clinical Oncology 15: p 572
18.
Zurück zum Zitat Rozzi A, Nardoni C, Corona M, Restuccia MR, Fabi A, Bria E, Minniti G, Lanzetta G (2011) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 19(5):697–701. doi:10.1007/s00520-010-0893-y PubMedCrossRef Rozzi A, Nardoni C, Corona M, Restuccia MR, Fabi A, Bria E, Minniti G, Lanzetta G (2011) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 19(5):697–701. doi:10.​1007/​s00520-010-0893-y PubMedCrossRef
20.
Zurück zum Zitat Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T (2007) Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5(8):374–380PubMed Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T (2007) Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5(8):374–380PubMed
21.
Zurück zum Zitat Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21(7):1373–1378PubMedCrossRef Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21(7):1373–1378PubMedCrossRef
22.
Zurück zum Zitat Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458–1465PubMedCrossRef Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458–1465PubMedCrossRef
23.
Zurück zum Zitat Roila F (2004) Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12(6):446–453. doi:10.1007/s00520-003-0553-6 PubMedCrossRef Roila F (2004) Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12(6):446–453. doi:10.​1007/​s00520-003-0553-6 PubMedCrossRef
26.
Zurück zum Zitat Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5):1151–1161PubMedCrossRef Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5):1151–1161PubMedCrossRef
27.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed
28.
Zurück zum Zitat Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24(6):547–561PubMedCrossRef Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24(6):547–561PubMedCrossRef
29.
Zurück zum Zitat Grunberg SM, Aapro, M.S (2012) Education Session on Antiemetics: Current standards, emerging approaches, and persistent gaps. In: American Society of Clinical Oncology Annual Meeting Grunberg SM, Aapro, M.S (2012) Education Session on Antiemetics: Current standards, emerging approaches, and persistent gaps. In: American Society of Clinical Oncology Annual Meeting
30.
31.
Zurück zum Zitat Farrell C, Brearley SG, Pilling M, Molassiotis A (2013) The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support Care Cancer 21(1):59–66. doi:10.1007/s00520-012-1493-9 PubMedCrossRef Farrell C, Brearley SG, Pilling M, Molassiotis A (2013) The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support Care Cancer 21(1):59–66. doi:10.​1007/​s00520-012-1493-9 PubMedCrossRef
32.
Zurück zum Zitat Tendas A, Sollazzo F, Niscola P, Cupelli L, Mauroni MR, D’Apolito A, Pilozzi V, Cacciaraichi S, Viggiani C, Pignatelli AC, Annibali O, Mengarelli A, Dentamaro T, de Fabritiis P, Arcese W (2013) Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score. Support Care Cancer 21(1):5–6. doi:10.1007/s00520-012-1550-4 PubMedCrossRef Tendas A, Sollazzo F, Niscola P, Cupelli L, Mauroni MR, D’Apolito A, Pilozzi V, Cacciaraichi S, Viggiani C, Pignatelli AC, Annibali O, Mengarelli A, Dentamaro T, de Fabritiis P, Arcese W (2013) Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score. Support Care Cancer 21(1):5–6. doi:10.​1007/​s00520-012-1550-4 PubMedCrossRef
33.
Zurück zum Zitat Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW (2000) Effects of computerized physician order entry on prescribing practices. Arch Intern Med 160(18):2741–2747PubMedCrossRef Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW (2000) Effects of computerized physician order entry on prescribing practices. Arch Intern Med 160(18):2741–2747PubMedCrossRef
34.
Zurück zum Zitat Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16(2):771–778PubMed Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16(2):771–778PubMed
35.
Zurück zum Zitat Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15(1):116–123PubMed Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15(1):116–123PubMed
Metadaten
Titel
Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice
verfasst von
Mary Lou Affronti
Susan M. Schneider
James E. Herndon II
Susan Schlundt
Henry S. Friedman
Publikationsdatum
01.07.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2136-0

Weitere Artikel der Ausgabe 7/2014

Supportive Care in Cancer 7/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.